Dermata Therapeutics (DRMA) Cash & Equivalents (2020 - 2026)

Dermata Therapeutics' Cash & Equivalents history runs 7 years deep, the most recent figure standing at $6.9 million for Q1 2026.

• In Q1 2026, Cash & Equivalents fell 28.4% year-over-year to $6.9 million; the TTM figure through Mar 2026 stood at $6.9 million (down 28.4% YoY), while the FY2025 annual figure was $7.5 million, up 137.92% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $6.9 million, down from $7.5 million in the prior quarter.
• The five-year high for Cash & Equivalents was $10.6 million in Q2 2022, with the low at $3.2 million in Q4 2024.
• The 5-year median for Cash & Equivalents is $6.9 million (2026), against an average of $7.0 million.
• The sharpest annual moves came in 2022 and 2024: Cash & Equivalents surged 2387.79% in 2022, then plunged 57.5% in 2024.
• Dermata Therapeutics' Cash & Equivalents stood at $6.2 million in 2022, then gained by 19.18% to $7.4 million in 2023, then slumped by 57.5% to $3.2 million in 2024, then soared by 137.92% to $7.5 million in 2025, then fell by 7.67% to $6.9 million in 2026.
• Business Quant data shows DRMA's Cash & Equivalents at $6.9 million in Q1 2026, $7.5 million in Q4 2025, and $4.7 million in Q3 2025.